Targeting Tumor Necrosis Factor Pathways in Psoriatic Diseases: The Next Step

Preclinical models suggest that specific blockade of TNFR2 may significantly reduce inflammation and ameliorate signs of psoriatic diseases, while maintaining normal immune response in the host, including the ability to combat infection and cancer. In this article, M. Elaine Husni, MD, MPH, highlights her latest research and discusses her plans to use her new R01 grant to continue her translational work.